Medical network - on April 14 

 

Domestic replace imported medical devices in the future 

 

A stent in the treatment of cardiovascular disease with, in the first foreign product unify the whole country, the unit price is as high as nearly 30000 yuan. As domestic support the launch of the latest bid price has fallen to below ten thousand dollars. For China residents health medical equipment localization of the Gospel, has attracted much attention in recent years. 

 

Recently, several domestic disclosure of annual reports of listed companies, according to localization further acceleration of medical apparatus and instruments. Thanks to the support of policy and focus on innovation, China imported medical instruments and medical equipment in some fields have and running stage, "import substitution" effect will be more apparent in the future. 

 

Annual report disclosure in succession watch for medical devices industry 

 

Hong Kong listed companies, a leading medical device company, Shanghai minimally invasive medical group, according to the results released recently companies achieve sales revenue of nearly $390 million in 2016, after the exchange rate influences year-on-year growth of 6.6%. Profits of $15.1 million, and the losses of $11.4 million over the same period last year. 

 

"The new policy, new opportunities, as well as the pursuit of security quality, promotes the development of innovative, scale and internationalized enterprises." Minimally invasive medical Chang Zhaohua, chairman and chief executive said. 

 

According to the results, in 2016 the core businesses of minimally invasive cardiovascular interventional products sector revenue of $138 million, up 11.8% year-on-year. It is worth mentioning that minimally invasive independent research and development of the third generation of drug-eluting stents "fire eagle sales revenue growth of 127%, including 212% of growth in overseas markets. 

 

Minimally invasive orthopedic devices by international acquisition and also keeps stable business growth, especially the development of Chinese orthopaedic business rapidly, joint product sales growth of 32%, far higher than the market average. 

 

In addition to the focus of medical apparatus and instruments listed company, is with big health business fosun medicine, medical apparatus and instruments of performance is also very interesting. Results showed that 2016 fosun medical devices and diagnostic business sales income of 2.653 billion yuan, up 18.23% from a year earlier, higher than 14.83% of the pharmaceutical manufacturing sector. 

 

It is worth mentioning that by fosun medicine exclusive distribution of the Da Vinci surgical robot in China, in 2016 in mainland China and Hong Kong since about 19000 cases, the growth of about 54% in 2015. See great prospects for medical devices industry, fosun pharma last September announced that the United States with the holders of the Da Vinci surgical robot technology, intuitive medical device companies set up joint ventures in Shanghai, the main research and development, production and sales for the early diagnosis and treatment of lung cancer products, to use its leading position in the field of minimally invasive surgery robot, promote the development and improvement of fosun medical equipment business. 

 

Policy support capital in favor of medical apparatus and instruments into the eyes of investors "beacon" 

 

State support for the domestic medical equipment, is a delegate with minimally invasive the key to the continued growth of the domestic medical equipment enterprises. 

 

Printed and distributed by the state council put forward "made in China 2025", to improve the innovative ability of medical equipment and the level of industrialization, focus on developing imaging equipment, medical robot, such as high performance medical device, and the degradation of stents high value medical consumables. 

 

Subsequently, the state food and drug supervision bureau, corresponding measures introduced to listed in the national science and technology major projects or focus on research and development plan for urgent clinical needs by medical equipment and medical equipment for prior approval. 

 

At present, these policies have been fall to the ground. Recently, total bureau of national food drug safety continuously released more batch of innovative medical equipment special request for approval and prior approval application review of results. "The approval policies more clear directivity, namely for diagnosis of rare diseases, malignant tumor, diseases of old age and childhood diseases." Citic securities researcher tian strengthen said. 

 

Capital market for medical equipment industry "thought". Back in 2016, the health industry, including pharmaceuticals, medical devices and medical services of mergers and acquisitions amount of $36.2 billion, 8 cases of health care investment transactions over $1 billion, of which 3 cases for medical apparatus and instruments, including citic $1 billion privatization Biosensors, worth nearly $1.2 billion in the investor of the China privatization of umbilical cord blood bank group and other excellent investment targets for medical devices industry has maintained a high enthusiasm. Recently, minimally invasive, heart pulse medical technology co., LTD. Announced introducing huaxing, cicc has professional background strategic investors, valued at 1.8 billion yuan, the financing of more than 500 million yuan. 

 

Fosun medicine, plans to increase investment in 2017, we will continue to strengthen medical equipment research and development, manufacture and sales, at the same time give a full play to the superiority of the international aspect, on the basis of positive integration vigorously expand the cooperation with foreign enterprises, in order to realize the scale of the medical equipment business growth. 

 

From "run" to "and" strengthening innovation improve quality of domestic enterprises 

 

In the international market, medical apparatus and instruments is a life science, machinery, electronics, polymer materials, and other areas of the multi-disciplinary cross, belongs to the high technology and capital intensive industries. Due to the high barriers to entry, profitable, has always been the focus of the global each big enterprise compete for. 

 

Statistics show that in 2016 the global medical device industry dominated the top 10 were European and us companies. The top three of medtronic, Johnson &johnson and GE medical, sales revenue of $28.8 billion, 25.1 billion and 17.6 billion respectively. 

 

Although compared with the international market, the domestic medical device companies such as weak small scale, technical level, product homogeneity competition etc, but with the improving of the enterprise independent innovation consciousness, the continuous improvement of technical level, and the government's policy support of medical devices industry, healthy development of the domestic medical equipment market gradually, has sprung up a group of leading technology of leading enterprises. 

 

Rich in medical resources in Shanghai, according to the medical equipment after-sales survey in 2016, there are five categories in 14 categories homebred brand service satisfaction is the first place. The Chinese medical association medical engineering branch, said commissioner li bin, director of the incoming in some niche, at present domestic medical equipment and imported medical instruments have and running stage. 

 

In addition, the domestic medical equipment also actively explore the international market. Minimally invasive in 2016 "fire eagle support added seven registered, to further expand the South American and Asian markets. At the same time, minimally invasive and also focus on the aorta intracavitary repair of medical equipment company Lombard, reached a strategic cooperation, will be in China and Brazil exclusive Lombard, two new innovative products. 

 

At present, China's per capita medical expenses is far lower than the European and American developed countries. Statistics show that China's drugs and devices of the ratio of the market size is 4.3, while developed countries and in mature markets YaoXie ratio is 2.0. With the accelerating the aging of the population, and gradually promote new diagnostic technology, end demand for medical devices industry will continue to maintain rapid growth, the current layout of medical equipment in the future will have huge development space. 

 

"From the medical sector, in vitro diagnostic, cardiovascular interventional devices, medical imaging, orthopaedic implants is the first four big niche. From the technology development trend, molecular diagnosis and minimally invasive surgical instruments, biological materials and biological implants is the growth point of the future." Huatai securities research report pointed out that in terms of domestic capital market, the policy encourages areas, have the ability to implement import substitution of domestic medical equipment enterprises, is a notable investment direction.